- Home
- SBET vs REPL Comparison
SBET vs REPL Comparison
Compare SBET & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBET | REPL |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SBET | REPL |
|---|---|---|
| Price | $5.88 | $22.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $16.50 | ★ $23.33 |
| AVG Volume (30 Days) | ★ 9.6M | 3.0M |
| Earning Date | 11-06-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | N/A |
| Revenue This Year | $86.67 | N/A |
| Revenue Next Year | $39.45 | $513.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $4.46 | $1.50 |
| 52 Week High | $12.29 | $22.72 |
Technical Indicators
Market Signals| Indicator | SBET | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 31.35 | 81.70 |
| Support Level | $5.06 | $7.11 |
| Resistance Level | $5.90 | N/A |
| Average True Range (ATR) | 0.40 | 1.45 |
| MACD | -0.11 | 0.85 |
| Stochastic Oscillator | 5.03 | 96.65 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.